188 related articles for article (PubMed ID: 34620015)
1. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
3. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
5. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
Fu Y; Li H
Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
7. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
10. Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women.
Farahani H; Amri J; Alaee M; Mohaghegh F; Rafiee M
Lab Med; 2020 Nov; 51(6):620-627. PubMed ID: 32537654
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
12. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
13. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
14. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
16. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
17. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
18. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
19. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
20. The potential value of serum chemerin in patients with breast cancer.
Song Y; Zhu X; Lin Z; Luo L; Wen D
Sci Rep; 2021 Mar; 11(1):6564. PubMed ID: 33753802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
